Please login to the form below

Not currently logged in
Email:
Password:

Priority Medicines

This page shows the latest Priority Medicines news and features for those working in and with pharma, biotech and healthcare.

EMA sees approval numbers rise in 2018

EMA sees approval numbers rise in 2018

The EMA has made similar moves in recent years with its own ‘accelerated assessment’ routes for priority innovations, such as the Priority Medicines scheme (PRIME), which hits its third year in ... Lastly, the EMA’s key human medicines committee,

Latest news

More from news
Approximately 2 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    In March 2017, AZ’s targeted lung cancer drug Tagrisso was one of the first medicines to gain approval through the Chinese Food and Drug Administration (CFDA)’s Priority Review pathway, ... This means the out-of-pocket cost for healthcare has fallen,

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    The European Medicines Agency (EMA) is no different offering five routes that can hasten approval, under certain conditions. ... The most recently added – the PRIority Medicines (PRIME) scheme – reached its two-year anniversary in March 2018. .

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    The sickle cell programme has also been named on the FDA’s Regenerative Medicine Advanced Therapy designation (RMAT), a new fast-track specifically aimed at helping these cutting edge medicines gain ... PRIME (The PRIority Medicines scheme) provides

  • The real-world data conundrum The real-world data conundrum

    Regardless of what the actual total costs are, though, it is certain that, with very few exceptions, the era of blockbuster drugs is over and the demand for stratified medicines, affordable ... diseases. At a more fundamental level, though, availability

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    In the first quarter of 2016, the EMA launched a scheme for PRIority MEdicines (PRIME), to optimise development plans and provide accelerated assessment for medicines that are of major interest for ... In 2016 special approval pathways and designations

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics